Hong Kong, China

Ning Man Cheng

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Ning Man Cheng

Introduction

Ning Man Cheng is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of human malignancies. With a total of 2 patents, his work focuses on innovative methods that leverage biochemical processes to combat cancer.

Latest Patents

Ning Man Cheng's latest patents include a groundbreaking pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation. This invention provides an isolated and substantially purified recombinant human arginase that possesses sufficiently high enzymatic activity and stability. This ensures adequate arginine depletion in patients, which is crucial for effective treatment. The invention also encompasses a pharmaceutical composition that includes the modified enzyme and outlines methods for treating diseases using this composition.

Career Highlights

Ning Man Cheng is associated with Bio-Cancer Treatment International Limited, where he applies his expertise in developing innovative cancer therapies. His work is characterized by a commitment to improving patient outcomes through scientific advancements.

Collaborations

Some of his notable coworkers include Yun Chung Leung and Wai Hung Lo, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Ning Man Cheng's contributions to cancer treatment through his innovative patents highlight the importance of research in pharmaceuticals. His work continues to pave the way for new therapeutic approaches in the fight against malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…